Member Info for OAPK20

Hopefully 85-90% or higher would be incredible.

Nothing since 10th August 2023. But tweeting “ @Cizzle is working hard to develop a clinical test for the CIZ1B biomarker which is highly associated with early-stage lung cancer”

Is it developed or not?

“ The next steps are to finalise standard production and operating protocols and to commence clinical trials that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA. The Company will then extend that to other key markets and will extend its use through regulatory approval with the FDA in the USA, the EMA for a CE mark in Europe, the MHRA in the UK for UKCA approval, and with the appropriate regulatory groups elsewhere in the world including China.”

Occam - I used to hold here but no longer following the current board announcing on 2nd May 2023 - "Therefore, the Board has decided to evaluate over the coming weeks a range of financing options for the Company, including how Plant Health Care might access non-dilutive and strategic capital to support its growth ambitions. As part of this process, the Board intends to consult with shareholders as to whether AIM remains the right capital market for Plant Health Care to achieve its ambitions"

That destroyed any trust in what could have been a superb company. The dual listing, in my view, remains indicative of this Boards ambitions to delist from AIM and gain a full listing in the US. "

18/05/23 - This didnt inspire much confidence "Whilst there are various perspectives within the shareholder base with regards to the listing on AIM and there is a broad acceptance that the Company is currently under-valued, there is clearly a prevailing view that the Company should remain listed. Having considered the feedback in full, the Board is pleased to confirm, therefore, that the Company remains committed to its listing on AIM, including for any potential funding needs."

Also Scobie Ward has increased their holding (and influence) to 13.1% whilst Richard Griffiths has reduced their holding to 5.54%.

The current SP suggests I made the correct choice for me. Until there is a new board in place who are committed to growing this company as a UK listing its not for me. Still love the products and what the company as a whole are trying to achieve but my view is the current board care little for PI's and would think nothing of delisting from aim with zero thought or notice to PI's.

Be interesting to see if Richard Griffiths remains a seller and clears out fully from PHC.

Until there is a Board change or PHC's future listing is confirmed whether AIM or NASDAQ ill keep watching from the side.

Precision Cut Cancer Tissue slices as human model for the testing of immune-modulatory compounds

$10 to get their £3.25M valuation. Nothing less

;-)

Wooooosssaaaaaahhh

With everything happening you’d think CIZ wouldn’t be shouting from the rooftops about their CIZ1b biomarker test detecting Stage 1 lung cancer. There must be something to shout about surely after decades of research, testing and development.

Tweets about working hard aren’t doing anything

5 days later. That can’t be right. Shady as

Tech I do still disagree. ;-)

Or later?

So will there be a share consolidation with 3,715,710,763 Ordinary Shares in issue with the next fundraise?

Background

Lung cancer is the leading cause of cancer death for both men and women with 127,070 deaths expected in

the U.S. in 2023. An estimated 238,340 new cases of lung cancer will be diagnosed in 2023. Trends in both

new cases and deaths have been decreasing for men and women following historical patterns of smoking

since 1965. The release of the 1964 Surgeon General’s Report on the health hazards of cigarette smoking

and tobacco control efforts have led to dramatic declines in cigarette consumption and consequently, lung

cancer incidence and mortality.

If lung cancer is found at an earlier stage, when the cancer is small and has not spread, it is more likely to be

treated successfully. Research has shown that access to yearly low-dose CT (LDCT) scans to screen people

at higher risk of lung cancer can save lives. Yet despite recommendations for lung cancer screening since

2013 from both the American Cancer Society and the U.S. Preventive Services Task Force (USPSTF), uptake

among eligible individuals is extremely low. Barriers to lung cancer screening include lack of insurance

coverage, out of pocket costs, and provider and public awareness of the availability and benefit of

screening. In 2020, there were approximately 8.5 million adults eligible for lung cancer screening and

approximately 552,500 or 6.5% were screened for lung cancer that year. Critical steps are needed to

increase lung cancer screening rates across the country and also increasing to access comprehensive

cessation benefits, especially among individuals with limited incomes that are disproportionately burdened

by lung cancer.

H.R. 4286 Bill Summary

Introduced by Representative Brian Higgins (D-NY-26) and Representative Kathy Castor (D-FL-14) the

“Increasing Access to Lung Cancer Screening Act:”

➢ Provides coverage without cost-sharing for lung cancer screening as recommended by USPSTF to

the traditional Medicaid population.

➢ Provides coverage for tobacco cessation as recommended by the USPSTF to the traditional Medicaid

population.

➢ Eliminates prior authorization requirements for lung cancer screening for Medicare and private

insurers.

➢ Establishes a $10 million lung cancer screening education and outreach campaign at the

Department of Health and Human Services.

➢ Requires a GAO report on the population diagnosed with lung cancer but not recommended for

screening.

ACS CAN’s Position

ACS CAN supports H.R. 4286 to eliminate barriers and increase access to lung cancer screening and expand

coverage for tobacco cessation

Previously posted but worth a read for anyone who hasn’t read it. State by state toll of lung cancer and Medicaid coverage.

https://www.lung.org/getmedia/186786b6-18c3-46a9-a7e7-810f3ce4deda/SOLC-2023-Print-Report.pdf

Bron it’s frustrating that CIZ tweet as they do as it is usually followed by selling. The main thing is to date there have been no TR1’s for reducing holdings.

Wonder if there’s enough buy pressure to break resistance this week.

856,667 @2.35 - 16:30:12 shows as a sell.

Tweet (Pump) big sells

Tweet (Pump) big sells

14,471,249 Options can be exercised by directors @ 2.19376p per share after 7th March.

Results for the year ended 31 December 2023 around 27th April.

So trial or validation? Do they have the requisite clinical sample sets for validation…DYOR

Are the Heads of terms going to become a full commercial agreement … Bill knows where it’s at

Production of a UKCA, CE marked and/or FDA 510(k) cleared product, following successful validation on retrospective clinical sample sets and control cohorts

-- Market launch and preparation for a clinical trial to support NHS and other global healthcare providers

Maybe ask if FairJourney Biologics have produced the goods

“ In parallel, new projects have been initiated to evaluate the use of CIZ1B for the detection of other cancers, which has led to an initial focus on breast cancer, which could widen the utility of this important cancer biomarker.”

Must be the Myles McN fella tweeting he’s long. Never a good sign.

Ok

Cash flow generated from operations increased to $142.5 million, an 18% increase from the prior year.

Protein Sciences Segment

The Company’s Protein Sciences segment is one of the world’s leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment’s second quarter fiscal 2024 net sales were $197.7 million, a decrease of 3% from $203.9 million for the second quarter of fiscal 2023. Organic revenue for the segment declined 4%, with foreign currency exchange having a 1% favorable impact. Protein Sciences segment’s operating margin was 40.3% in the second quarter of fiscal 2024 compared to 43.8% in the second quarter of fiscal 2023. The segment’s operating margin decreased primarily due to unfavorable volume and product mix.

Diagnostics and Genomics Segment

The Company’s Diagnostics and Genomics segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Genomics segment also develops and provides spatial biology products as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Genomics segment’s second quarter fiscal 2024 net sales were $75.4 million, an increase of 11% from $68.0 million for the second quarter of fiscal 2023. Organic revenue growth was 5% for the second quarter of fiscal 2024, with acquisitions having a 5% impact and foreign exchange having a favorable impact of 1%. The Diagnostics and Genomics segment’s operating margin was 6.0% in the second quarter of fiscal 2024 compared to 12.2% in the second quarter of fiscal 2023. The segment’s operating margin decreased primarily due to the Lunaphore acquisition.